7-9 Jul 2021 Angers (France)

Plenary speakers

 

B Sarmento Bruno Sarmento is Principal Investigator at Institute of Biomedical Engineering/Institute for Research and Innovation in Health (INEB/i3S), University of Porto (UP), and Associate Professor at Instituto Universitário de Ciências da Saúde (IUCS), Portugal.

 He graduated in Pharmaceutical Sciences at the University of Porto (PT) in 2002 and completed a PhD in Pharmaceutical Nanotechnology at UP in 2007, in collaboration with Queen’s University (CA), University of Copenhagen (DK) and Queen’s University (Canada). From 2007 to 2012 he held a research assistant position at UP. In 2008 he was appointed Assistant Professor at IUCS. He also co-founded Inovapotek in 2008, and is member of its advisory board. In 2012 he became Associated Researcher at INEB, where established an independent team. He was appointed as Assistant Researcher at INEB/i3S in 2016, and Principal Investigator in 2019.

 His current research are focused on the development of drug delivery systems, with special attention on nanotechnology, and their application to the pharmaceutical and biomedical fields. He is interested in engineering targeted nanomedicines by identifying novel biological targets, proposing new functional ligands and producing tailored nanoplatforms for the delivery of therapeutic molecules for managing cancer, infection and metabolic diseases. Bruno Sarmento has been pioneering in bioengineering nanoparticles for targeted delivery of anti-cancer drugs to tumors. He has a thoroughly study on the design and validation of nanoparticles for the treatment of colorectal cancer, focus on the CD44v6 and CEA receptors, and modulate the pharmacokinetics of anti-cancer. Bruno Sarmento also proposed nanomedicines for intranasal delivery of bevacizumab as a glioblastoma anti-angiogenic treatment and demonstrated the potential impact of intracellular delivery of antibodies in the reduction of intracellular levels of angiogenic factors. He has also specialized in tissue engineering models to validate functionalized nanomedicines and to perform in vitro/in vivo correlation. So far, he has supervised/co-supervised 14 Post-Docs (11 completed), 40 PhD students (32 completed) and 38 MSc students (35 completed), and 13 researcher assistants. He published more than 370 (total citations in Scopus 11700; H-index 54 and in GoogleScholar 16720; H-index 65). His work has attracted funding of >15 million €, from public and private entities, including EU, FCT, CESPU and pharmaceutical and medical devices industries (Gilead, Ferring, Aché, Ceramed). Bruno Sarmento was the first Chair of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society.

 

-----------------------------------------------------------------------------------------------------------------------------------------------------------------

 S Mura Dr. simona Mura holds a Master's degree in Pharmacy and Chemistry from the University of Cagliari (Italy). She obtained her PhD in Chemistry and Technology of Drug in 2009 at the same university working on the design and in vitro evaluation of novel vesicular systems for the topical delivery of drugs. She then joined the group of Professor Elias Fattal (Galien Institute, UMR CNRS 8612) at the University Paris-Saclay (France), as a post-doctoral researcher to study the lung toxicity of biodegradable nanoparticles designed for pulmonary drug administration.

In 2011, she has been appointed Associate professor in the same University under the «CNRS-Higher Education chairs» program (Chaires d 'excellence CNRS) and she integrated the team of Professor Patrick Couvreur. Since 2015 she is also regularly hosted as a Visiting Associate professor at the University of Osaka (Japan). Her research focuses on the design of biomimetic drug delivery systems and the construction of in vitro and in vivo models for a relevant preclinical assessment of the therapeutic efficacy of nanomedicines. She is (co)author of 55 peer review articles in international journals, 4 book chapters and co-editor of 1 book. Dr Mura has also been appointed Junior member of the prestigious Institut Universitaire de France (IUF) in 2017.

--------------------------------------------------------------------------------------------------------------------------------------------------------------------

F. Caputo Dr. Fanny Caputo is a deeply passionate researcher with experience in the physico-chemical characterization and pre-clinical evaluation of nanoparticle-enabled medical products (pharmaceuticals and medical devices). She is involved in the development of standardized methods for the characterization of nanomaterials (e.g. with the ASTM E56) and in regulatory science. She is part of the European Nanomedicine Technology Platform (ETPN), where she chairs the Safety and Characterization Working Group, and is the contact point of the European Nanomedicine Characterization Laboratory (EUNCL, http://www.euncl.eu/).  

Fanny is involved in multiple Horizon 2020 consortia and industrial projects aiming at developing, characterizing and scaling up nanopharmaceuticals and medical devices. She is also interested in nano-toxicology, e.g. in the safety assessment of nanomaterials in consumer products and of environmental nano-pollutant such as nano- and micro-plastics. She has been with SINTEF in Norway since 2019, and previously worked at CEA (Commissariat à l'Energie Atomique et aux Energies Alternatives) in France.

 

--------------------------------------------------------------------------------------------------------------------------------------------------------------------

P Loyer Dr. Pascal Loyer, is a senior Inserm investigator, leader of the team « Metals, Diseases and Vectorized Threapies », within the Institute “Nutrition, Metabolisms and Cancer” (https://numecan.fr/mether/), laboratory Inserm UMR1241-INRAE UMR1341-University of Rennes 1, Pontchaillou-Villejean, Rennes, France.

He obtained his PhD in Cellular and Molecular Biology from the University of Rennes 1 in 1993 followed by a postdoctoral training in the department of Tumor Cell Biology at the Saint Jude Children’s Research Hospital (Memphis, TN USA).

His work was first focused on the study of liver regeneration, the role of CDK1/CDK11 cyclin-dependent protein kinases and glutathione transferases during proliferation and apoptosis in hepatic cells. He also led pharmacotoxicology and metabolism studies in liver cells. In collaboration with T. Benvegnu (Ecole Nationale Supérieure de Chimie de Rennes-ENSCR), PA Jaffrès (CNRS UMR6521, Brest) and T. Montier (Inserm U1078, Brest), he developed new liposomes for gene transfer and created the SynNanoVect platform of the Biogenouest network dedicated to the vectorization of biomolecules (http://www.univ-brest.fr/synnanovect). More recently, in collaboration with S. Cammas-Marion (CNRS, ENSCR), they characterized and optimized new nanoparticles (NPs), produced from (co)polymers derived from poly (malic acid) (PMLA) for the encapsulation of radionuclides and drugs. Their current project is to use peptides recently identified for their strong hepatic tropism to functionalize PMLA-based NPs embedding organometallic complexes and the production of new peptide/chelate conjugates complexed with radionuclides (64/67Cu, 90Y, 188Re) for the diagnosis and treatment of hepatocellular carcinoma.

--------------------------------------------------------------------------------------------------------------------------------------------------------------------

JP Benoit Pr. Jean Pierre Benoit obtained a Pharmacy degree at the University of Tours in 1976, an advanced degree and doctorate in macromolecular organic chemistry at the University of Mans between 1977 and 1979. Afterwards, he obtained a PhD in Pharmaceutical Sciences at the University of South Paris in 1983. Since then, he pursued an academic career as research assistant and associate Professor at the University of South Paris and then as full Professor and Hospital Pharmacist at the University of Angers. Here, he created in 2001 a French National Institute of Health and Medical Research (INSERM) / University of Angers joint research team, the "Biomimetic micro and nanomedicine" unit, that he headed during 16 years until 2017.  

JP Benoit has been a pioneer in drug delivery, setting up and managing multi-disciplinary teams - formed of physicists, chemists, galenists, biologists and clinical physicians - highly committed to the development of innovative and translational approaches for the benefit of the patients. The research activities of JP Benoit have been focused on the conception, development, characterization and preclinical evaluation of pharmaceutical vectors (nanomedicines or micromedicines) able to deliver pharmacological molecules or cells to target tissues. The main applications of its research have been cancer treatment and tissue engineering.

Together with its hospital, academic and research commitments, JP Benoit invested in the promotion of academic research by creating the Microencapsulation Centre in Angers (1992), the Mainelab SA (1999) and finally Carlina Technologies (2010), in the field of nanomedicines. This activity has enabled him to create around thirty jobs in Angers, outside the academic sector.

JP Benoit has been awarded by several (inter)national awards during its career, including the Pharmaceutical Sciences World Congress Research Achievement Award in 2010, and the Grand Prix of the French National Academy of Pharmacy (Notoriety Prize) in 2011.

He is presently the President of the local charity organization, la Ligue contre le Cancer, dedicated to the help and the support of patients suffering from this disease as well as the financial support of the research in this area.

-----------------------------------------------------------------------------------------------------------------------------------------------------------------

H. Haas Dr. Heinrich Haas has more than 20 years of experience in academic research and industrial pharmaceutical development. After he received his PhD in physical chemistry, Dr Haas researched lipid membranes and organized biomolecular systems. His professional focus is on colloidal/nanoparticulate formulations for targeted drug delivery with therapeutic and diagnostic applications.

Before joining BioNTech RNA Pharmaceuticals GmbH (former Ribological GmbH), he was responsible for a variety of projects in biopharmaceutical research and development, ranging from the exploration of novel colloidal therapeutic and diagnostic carriers to up-scaling and development of market-compliant manufacturing methods for liposomes products.

After joining BioNTech RNA pharmaceuticals GmbH in 2010, he helped build the formulation development and analytics unit, which develops formulations for the delivery of RNA and small molecules. He has an active record of publications in peer-reviewed journals and patent applications in the field of drug delivery.

Online user: 3 Privacy
Loading...